Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).
Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).

1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).

Acupuncture

Tumor, Brain

Skull Base Tumor

Cerebellopontine Angle Tumor

Complication of Treatment

Quality of Life

Neuromuscular Blockade

Center for Traditional Medicine, Taipei VGH

Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base

Evaluate the quality of life after acupuncture treatment, use WHOQOL-BREF Taiwan Version questionnaire. Scale: 0~100, higher scores, better life quality. Counted by each time recording and using mode conversion to get final scale.

measurement for pain,to assess the pain degree. Scale: 0~100 mm, higher scores, higher pain . Counted by each time recording.

Evaluate the quality of life for " the patients of CPA tumor in skull base " after acupuncture treatment,there are four parts,physiology,social and family, emotion,function.Scale: 0~100, higher scores, better life quality. Counted by each time recording and using mode conversion to get final scale.

measurement and evaluate the level for the patients of facial paralysis after surgery of CPA tumor in skull base.Measure the upwards and outwards movement situation of eyebrows and mouth. Each reference point scores 1 point for each 0.25 cm movement, up to a maximum of 1 cm. The scores are then added together, to give a number out of 8.After that, the scale of facial paralysis corresponding to the score was divided into five levels, with the first level being the mildest and the fifth level being the most severe.

Taipei Veterans General Hospital, Taiwan

Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.

Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.

Temporomandibular Joint Pain

Radiofrequency

Montreal General Hospital

TMD Pulsed Radiofrequency

Pulsed Radiofrequency As A Treatment For Mastecatory Muscle Pain In Temporomandibular Disorder Patients

using Numerical Rating Scale (NRS) at the end of the procedure (NRS post-procedure), and in the follow-up at 4 weeks and 12 weeks post-procedure.

by measurement of maximum mouth opening (MMO) in centimetres

By measurement of lateral jaw excursion in centimetres

By measurement of jaw protrusion in centimetres

JF Asenjo

Professor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.

Subjects received lapatinib for 1500 mg by mouth daily for 10 days prior to surgery for vestibular schwannoma resection

Lapatinib

Control subjects did not receive any intervention prior to surgery for vestibular schwannoma resection

Control

Total

Sex: Female, Male

Region of Enrollment

KPS is a physician-reported outcome measuring an individual's functional impairment. Scores range from 0% (death) to 100% (normal no complaints; no evidence of disease).
Specific to these results, 70% represents an ability to care for self; unable to carry on normal activity or to do active work, and 90% represents an ability to carry on normal activity; minor signs or symptoms of disease.

Karnofsky Performance Status (KPS)

Patients with a diagnosis of NF2

Steady-state plasma concentrations of lapatinib (ng/mL) at time of surgery, 10-13 days from starting drug.

Subjects received lapatinib 1500 mg by mouth for 10 days prior to surgery for vestibular schwannoma resection

Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection

Count of tissue samples with lapatinib concentration >3uM

Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
lapatinib: 1500 mg lapatinib by mouth per day for 10 days

To Assess Whether Lapatinib Can Reach a Minimum Tumor Concentration Level of >3uM in VS After Oral Dosing.

Assessed number of samples with high expression of phospho-ErbB2 in tissue at time of surgery

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection. Control subjects donate tissue at the time of surgery.

Assess the Level of ErbB2 Phosphorylation in VS.

Assess Markers of Tumor Proliferation and Cell Death in VS After Exposure to Lapatinib.

A comparison in the median lapatinib concentration (ng/g) in vestibular schwannomas associated with neurofibromatosis type 2 and sporadic vestibular schwannomas

Participants with vestibular schwannomas associated with a diagnosis of neurofibromatosis type 2

NF2 Associated VS

Participants with sporadic vestibular schwannomas (i.e. not associated with a diagnosis of neurofibromatosis type 2)

Sporadic VS

Explore the Difference in the Concentration of Lapatinib Achieved in NF2-related Versus Idiopathic VS.

Due to the sample sizes, a comparison between sporadic and NF2-related vestibular schwannomas could not be made. Instead we report the mutational status.

Seven participants had successful NF2 gene mutation analysis via exon scanning and MLPA.

Participants With Tissue Available for Gene Mutation Analysis

Perform NF2 Gene Mutation Analysis Via Exon Scanning and MLPA as Well as Protein Expression in All VS and Explore Differences Between Sporadic and NF2 Related VS.

Subjects received lapatinib 1500 mg by mouth for 10 days prior to surgery for vestibular schwannoma resection.

Control subjects did not receive any intervention prior to surgery for vestibular schwannoma resection.

Overall Study

Jaishri Blakeley

Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection. Control subjects donate tissue at the time of surgery. AEs were not collected in this group as there was no study intervention (i.e. they did not take the drug).

Vestibular Schwannoma

Neurofibromatosis 2

Acoustic Neuroma

Auditory Tumor

1500 mg lapatinib by mouth per day for 10 days

neuroma/glavobolja

Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base

TMD Pulsed Radiofrequency

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Najkompletnija baza ljekovitog bilja potpomognuta znanošću